News & Events

HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System

TUCSON, Ariz., March 23, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology has been successfully adapted for use with the QIAGEN GeneReader NGS System based on the results of initial technical feasibility tests. Results from samples tested with the HTG EdgeSeq DLBCL Cell of Origin Assay gene panel adapted for detection with the GeneReader NGS System showed strong correlation (r = 0.98) to data previously generated on the MiSeq sequencer.

full press release

Posted on:

Return To List

Page last updated December 20, 2017